Want to see NVST full AI Analyst Report?
NVST Stock Chart & Stats
$27.47
$0.16(0.61%)
At close: 4:00 PM EDT
$27.47
$0.16(0.61%)
Day’s Range― - ―
52-Week Range$18.77 - $30.42
Previous Close$26.33
Volume1.86M
Average Volume (3M)2.95M
Market Cap
$3.72B
Enterprise Value$5.00B
Total Cash (Recent Filing)$1.13B
Total Debt (Recent Filing)$1.59B
Price to Earnings (P/E)39.3
Beta0.96
Next Earnings
Nov 04, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.59
Shares Outstanding160,617,700
10 Day Avg. Volume2,664,299
30 Day Avg. Volume2,951,475
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)1.17
Price to Sales (P/S)1.34
P/FCF Ratio15.83
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue1.75
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda12.24
Forecast
1Y Price Target
$29.38Price Target Upside6.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)1.53
Revenue Forecast (FY)$2.88B
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue GrowthGrowth is broad across core dental equipment, consumables, diagnostics, and specialty products, indicating improving commercial execution rather than reliance on one product. Continued share gains and procedure-related demand can support durable revenue expansion over the next several quarters.
Improving Margins And Cash GenerationStrong cash conversion alongside expanding EBITDA margins improves Envista’s ability to fund research, commercial investment, acquisitions, and shareholder returns internally. This combination also provides greater resilience if equipment demand or dental practice spending moderates.
Flexible Balance SheetLow net leverage gives Envista meaningful financial flexibility to pursue acquisitions, invest in product development, and repurchase shares without placing excessive pressure on cash flows. That supports strategic execution while reducing balance-sheet risk through the planning period.
Bears Say
China VBP Pricing PressurePotentially significant China reimbursement-driven price reductions could directly pressure implant revenue and margins, even if management expects later volume or share recovery. The uncertainty around timing and net impact makes this a material multi-quarter earnings risk.
Thin And Volatile ProfitabilityA thin net margin leaves limited protection if pricing, demand, or operating costs deteriorate. The history of losses also shows that improved results have not yet established a fully stable earnings base, potentially constraining reinvestment and reducing downside resilience.
Cyclical Elective CategoriesExposure to elective implants and orthodontics makes part of Envista’s portfolio sensitive to practice investment decisions and regional economic conditions. Softer demand in important markets could moderate growth and make performance less consistent across geographic and product cycles.
NVST FAQ
What was Envista Holdings Corp’s price range in the past 12 months?
Envista Holdings Corp lowest stock price was $18.77 and its highest was $30.42 in the past 12 months.
What is Envista Holdings Corp’s market cap?
Envista Holdings Corp’s market cap is $3.72B.
When is Envista Holdings Corp’s upcoming earnings report date?
Envista Holdings Corp’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.
How were Envista Holdings Corp’s earnings last quarter?
Envista Holdings Corp released its earnings results on Aug 05, 2026. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.075.
Is Envista Holdings Corp overvalued?
According to Wall Street analysts Envista Holdings Corp’s price is currently Undervalued.
Does Envista Holdings Corp pay dividends?
Envista Holdings Corp does not currently pay dividends.
What is Envista Holdings Corp’s EPS estimate?
Envista Holdings Corp’s EPS estimate is 0.36.
How many shares outstanding does Envista Holdings Corp have?
Envista Holdings Corp has 160,617,700 shares outstanding.
What happened to Envista Holdings Corp’s price movement after its last earnings report?
Envista Holdings Corp reported an EPS of $0.41 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went down -4.366%.
Which hedge fund is a major shareholder of Envista Holdings Corp?
Currently, no hedge funds are holding shares in NVST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Envista Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.38 (6.97% Upside)
$29.38 (6.97% Upside)
Blogger Sentiment
Bullish
NVST Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 977.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.81%
12-Months-Change
Fundamentals
Return on Equity
3.08%
Trailing 12-Months
Asset Growth
-1.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Envista Holdings Corp
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
NVST Company Deck
NVST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported a strong quarter with broad-based revenue growth, meaningful margin expansion, large EPS and free-cash-flow improvement, a strengthened balance sheet and raised full-year guidance. Operational highlights included robust E&C performance, double-digit Spark growth, successful new product launches, and continued share gains. Headwinds and risks were manageable and largely named and quantified: China VBP-driven price pressure and timing uncertainty, a Q4 billing-day calendar headwind, tariff-related costs, and the end of a small deferral tailwind. Overall, management framed the issues as addressable while emphasizing continued momentum, investment in R&D and commercial initiatives, and confidence in the raised guidance.View all NVST earnings summariesNVST Revenue Breakdown
63.99% Specialty Products & Technologies
36.01% Equipment & Consumables

NVST Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$29.38
▲(6.97% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
0.84% Insiders
38.11% Mutual Funds
1.09% Other Institutional Investors
31.09% Public Companies and
Individual Investors












